Trial Profile
Phase I Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Plitidepsin (Primary) ; Gemcitabine; Sorafenib
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- Sponsors PharmaMar
- 06 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 06 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2009 New source identified and integrated (New Jersey Cancer Trial Connect).